Please activate JavaScript!
Please install Adobe Flash Player, click here for download
ePaper created 2014-10-06, 13:17:01 | version 1.33.00
14. Keeling D, Baglin T, Tait C, et al. Guidelines on oral anticoagulation with warfarin––fourth edition. Br J Haematol. 2011;154(3):311–24. 15. Jones M, McEwan P, Morgan CL, Peters JR, Goodfellow J, Currie CJ. Evaluation of the pattern of treatment, level of anticoagulation control, and outcome of treatment with warfarin in patients with non-valvar atrial fibrillation: a record linkage study in a large British population. Heart. 2005;91:472–7. 16. Gallagher AM, Setakis E, Plumb JM, Clemens A, van Staa TP. Risks of stroke and mortality associated with suboptimal anticoagulation in atrial fibrillation patients. Thromb Haemost. 2011;106(5):968–77. 17. Rose AJ, Hylek EM, Ozonoff A, Ash AS, Reisman JI, Berlowitz DR. Risk-adjusted percent time in therapeutic range as a quality indicator for outpatient oral anticoagulation: results of the Veterans Affairs study to improve anticoagulation (VARIA). Circ Cardiovasc Qual Outcomes. 2011;4(1):22–9. 18. Rose AJ, Hylek EM, Ozonoff A, Ash AS, Reisman JI, Berlowitz DR. Patient characteristics associated with oral anticoagulation control: results of the Veterans affairs study to improve anticoagulation (VARIA). J Thromb Haemost. 2010;8(10):2182–91. 19. Ansell J, Hirsh J, Hylek E, Jacobson A, Crowther M, Palareti G. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest. 2008;133:160S– 98S. 20. Lind M, Fahlen M, Kosiborod M, Eliasson B, Ode´n A. Variability of INR and its relationship with mortality, stroke, bleeding and hospitalisations in patients with atrial fibrillation. Thromb Res. 2012;129:32–5. 21. van Dolder BD, van Geest-Daalderop JJH, van’t Land RP, Levi MM, Piersma-Wichers G. De kunst van het doseren: Richtlijn, leidraad en informatie voor het doseren van vitamine K-antagonisten. Available from http://www.fnt.nl/. Accessed April 2014 (in Dutch). 22. Bezemer ID, Roemer WH, Penning-van Beest FJ, van Eekelen E, Kramer MH. INR control calculation: comparison of Dutch and international methods. Neth J Med. 2013;71(4):194–8. 23. Erkens PM, ten Cate H, Bu¨ller HR, Prins MH. Benchmark for time in therapeutic range in venous thromboembolism: a systematic review and meta-analysis. PLoS One. 2012;7(9):e42269. 24. Rosendaal R, Cannegieter S, van der Meer F, van der Meer F, Briet E. A method to determine the optimal intensity of oral anticoagulant therapy. Thromb Haemost. 1993;69(3):236–9. 25. Prentice RL, Williams BJ, Peterson AV. On the regression analysis of multiple failure time data. Biometrika. 1981;68(2):373–9. 26. Lin DY, Wei LJ. The robust inference for the Cox proportional hazards model. J Am Stat Assoc. 1989;84:1074–8. 27. Wallentin L, Yusuf S, Ezekowitz MD, et al. Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial. Lancet. 2010;376(9745):975–83. 28. Go´mez-Outes A, Terleira-Ferna´ndez AI, Calvo-Rojas G, Sua´rez-Gea ML, Vargas-Castrillo´n E. Dabigatran, rivaroxaban, or apixaban versus warfarin in patients with nonvalvular atrial fibrillation: a systematic review and meta-analysis of subgroups. Thrombosis. 2013;2013:640723. 29. Di Minno MN, Russolillo A, Di Minno A, Camera M, Parolari A, Tremoli E. Direct anticoagulant drugs to overcome limitations of vitamin K antagonists. A critical appraisal of data in atrial fibrillation patients. Expert Opin Emerg Drugs. 2013;18(1):9–23. 30. Giugliano RP, Ruff CT, Braunwald E, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013;369(22):2093–104. 31. Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet. 2014;383(9921):955–62. 32. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12):1139–51. 33. Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365(10):883–91. 34. Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11):981–92. 35. Rose AJ, Berlowitz DR, Ash AS, Ozonoff A, Hylek EM, Goldhaber-Fiebert JD. The business case for quality improvement: oral anticoagulation for atrial fibrillation. Circ Cardiovasc Qual Outcomes. 2011;4(4):416–24. Adv Ther